Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto)

Drug Overview

Lutetium Lu 177 vipivotide tetraxetan, marketed under the brand name Pluvicto, is a “Targeted Therapy” specifically classified as a radioligand therapeutic agent. It represents a precision medicine approach in oncology, delivering radiation directly to tumor cells expressing a specific biomarker.

• Generic Name: Lutetium Lu 177 vipivotide tetraxetan
• US Brand Name: Pluvicto
• Drug Class: Radiopharmaceutical (Radioligand Therapy)
• Route of Administration: Intravenous (IV) Injection/Infusion
• FDA Approval Status: Approved (March 2022)

What Is It and How Does It Work? (Mechanism of Action)

Lutetium Lu 177 vipivotide tetraxetan utilizes a mechanism known as receptor-targeted radionuclide therapy. It is designed to target cells that overexpress Prostate-Specific Membrane Antigen (PSMA), a transmembrane protein found in high levels on the surface of most prostate cancer cells.

Molecular Mechanism:

1. Targeting: The drug consists of a targeting ligand (vipivotide tetraxetan) chemically attached to a therapeutic radioisotope (Lutetium-177). The ligand binds with high affinity to the PSMA receptors on the surface of prostate cancer cells.
2. Internalization: Upon binding, the radiopharmaceutical complex is internalized (absorbed) into the cancer cell via endocytosis.
3. Radiation Emission: Once inside, the Lutetium-177 emits beta-minus particles (radiation). This radiation induces lethal DNA damage, specifically causing single-strand and double-strand breaks in the DNA of the tumor cell.
4. Cell Death: The accumulation of DNA damage triggers apoptosis (programmed cell death). Due to the limited range of beta particles (approximately 1 mm), the radiation also affects neighboring tumor cells (“cross-fire effect”) while minimizing damage to surrounding healthy tissue.

FDA-Approved Clinical Indications

Lutetium Lu 177 vipivotide tetraxetan is currently FDA-approved for the following indications:

• Oncological Uses:
  • Treatment of adult patients with Prostate-Specific Membrane Antigen (PSMA)-positive Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Eligibility Criteria: Patients must have previously been treated with:
    • An androgen receptor (AR) pathway inhibitor (e.g., abiraterone or enzalutamide).
    • A taxane-based chemotherapy regimen.
• Non-Oncological Uses:
  • None.

Dosage and Administration Protocols

The administration of Lutetium Lu 177 vipivotide tetraxetan requires a specialized nuclear medicine facility. The protocol involves a fixed dosing schedule.

Dose Adjustments for Organ Impairment:

• Renal Impairment: No dose adjustment is recommended for patients with mild to moderate renal impairment (CLcr ≥ 30 mL/min). The safety in severe renal impairment (CLcr < 30 mL/min) or end-stage renal disease has not been established; patients should be monitored closely for toxicity.
• Hepatic Impairment: No dose adjustment is recommended for patients with mild to moderate hepatic impairment.

Clinical Efficacy and Research Results

Recent clinical trials from 2020-2025 have solidified the efficacy of Lutetium Lu 177 vipivotide tetraxetan in advanced prostate cancer.

• VISION Trial (Phase 3):
  • Overall Survival (OS): Patients treated with Pluvicto plus standard of care showed a median OS of 15.3 months, compared to 11.3 months for those receiving standard of care alone (Hazard Ratio: 0.62).
  • Radiographic Progression-Free Survival (rPFS): The median rPFS was 8.7 months for the Pluvicto group versus 3.4 months for the control group.
• PSMAfore Trial (2024 Data):
  • In taxane-naive patients with mCRPC, Pluvicto demonstrated a statistically significant improvement in rPFS compared to a change in androgen receptor pathway inhibitor (ARPI).
  • rPFS: Median of 11.6 months vs. 5.6 months in the control arm.
  • These results suggest potential efficacy in earlier lines of therapy (pre-chemotherapy settings).

Safety Profile and Side Effects

While targeted, the radioactive nature of the drug entails specific safety risks, particularly to the bone marrow and kidneys.

Common Side Effects (>10%):

• Fatigue: Extreme tiredness or weakness.
• Dry Mouth (Xerostomia): Caused by radiation uptake in the salivary glands.
• Nausea and Vomiting.
• Anemia: Low red blood cell count.
• Decreased Appetite and Weight Loss.
• Constipation.

Serious Adverse Events:

• Myelosuppression: Severe reduction in blood cell counts, including Grade 3 or 4 anemia, thrombocytopenia (low platelets), and leukopenia/neutropenia (low white blood cells), increasing infection and bleeding risk.
• Renal Toxicity: Potential for kidney function decline due to radiation exposure during excretion.
• Secondary Malignancies: Long-term exposure to radiation may theoretically increase the risk of developing other cancers, such as Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).

Management Strategies:

• Hydration: Patients must drink fluids liberally before and after administration to flush the radiopharmaceutical from the kidneys and bladder.
• Blood Monitoring: Complete Blood Counts (CBC) must be performed before each dose to assess marrow recovery.
• Dose Modification: Treatment may be withheld, dose-reduced by 20% (to 5.9 GBq), or permanently discontinued if severe adverse reactions occur.

Research Areas

Current research is exploring the expansion of Lutetium Lu 177 vipivotide tetraxetan into earlier stages of prostate cancer, such as metastatic hormone-sensitive prostate cancer (mHSPC) (e.g., the PSMAddition trial). Additionally, clinical investigators are evaluating combinations with immunotherapy (e.g., checkpoint inhibitors like pembrolizumab) and PARP inhibitors to enhance DNA damage and immune recognition of tumor cells. There is currently no standard protocol combining this drug directly with stem cell therapies, although autologous stem cell support could theoretically be considered in cases of extreme marrow failure, though this is not standard practice.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• PSMA PET/CT Scan: Mandatory to confirm high PSMA expression in tumor lesions (using agents like Ga-68 PSMA-11).
• Laboratory Tests: Baseline Complete Blood Count (CBC), Serum Creatinine/eGFR (Kidney function), and Liver Function Tests (AST, ALT, Bilirubin).
• Pregnancy/Reproductive Status: Verification of partner pregnancy status; advise on contraception.

Precautions During Treatment:

• Radiation Safety: The patient retains radioactivity for a few days. They must maintain a safe distance from others, especially pregnant women and children.
• Hygiene: Flush the toilet twice after use, wash hands thoroughly, and wash soiled clothing separately to prevent radiation contamination of the household.

“Do’s and Don’ts” List:

• DO drink plenty of water (at least 2-3 liters) on the day of treatment and the days following to protect the kidneys.
• DO urinate frequently to reduce radiation exposure to the bladder.
• DO use effective contraception (condoms) during treatment and for 14 weeks after the final dose.
• DON’T sleep in the same bed as others for at least 3 days (or as advised by the radiation safety officer) after each infusion.
• DON’T engage in sexual activity for 7 days following administration.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content is intended for international patients and healthcare professionals and may not reflect the most current regulatory approvals in all jurisdictions. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or treatment protocol. Do not disregard professional medical advice or delay in seeking it because of something you have read in this document.